Odyssey Therapeutics, Inc. (ODTX)
Market Cap | n/a |
Revenue (ttm) | 3.00M |
Net Income (ttm) | -127.41M |
Shares Out | n/a |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | n/a |
Open | n/a |
Previous Close | n/a |
Day's Range | n/a |
52-Week Range | n/a |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About ODTX
Odyssey is a clinical-stage biopharmaceutical company led by a team and board of drug hunters seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. To accomplish this, we are developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Our most advanced programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, for which we intend to commence a Phase 2a monotherapy... [Read more]
News

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
BOSTON--(BUSINESS WIRE)--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.

Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics today announced the closing of a $213 million Series D financing.

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings
The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahea...

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...

Odyssey Therapeutics Begins IPO Rollout
Odyssey Therapeutics, Inc. aims to raise $100 million in an IPO to advance its drug pipeline for inflammatory and autoimmune diseases. Its lead candidate, OD-07565, is entering Phase 2a trials for the...

Autoimmune biotech Odyssey Therapeutics files for a $100 million IPO
Odyssey Therapeutics, a Phase 2-ready biotech developing precision therapies for autoimmune diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Odyssey Therapeutics IPO Registration Document (S-1)
Odyssey Therapeutics has filed to go public with an IPO on the NASDAQ.